Skip to content

Comparative Analysis of Platelet Rich Plasma and Electrical Muscular Stimulation versus Traditional Management in Complicated Wounds - A Randomized Controlled Trial

Comparative Analysis of Platelet Rich Plasma and Electrical Muscular Stimulation versus Traditional Management in Complicated Wounds - A Randomized Controlled Trial - A Trial of Innovative Therapies to Speed Up Recovery in Hard-to-Heal Wounds

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102234
Enrollment
Unknown
Registered
2025-05-12
Start date
2025-05-25
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complicated Wounds

Interventions

Intervention Group:Participants will receive a combination of Platelet-Rich Plasma (PRP) therapy and Electrical Muscular Stimulation (EMS) in addition to standard wound care. PRP will be prepared usin
Control Group:Participants will receive standard wound care, including cleaning, dressing changes, debridement if necessary, and pressure offloading where appropriate.

Sponsors

Combined Military Hospital Kohat
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: • Participants must be aged 18 years or older. • Participants should have chronic or complicated wounds, including diabetic foot ulcers, pressure ulcers, venous leg ulcers, or post-surgical or trauma-related wounds, that have not shown significant healing after at least 4 weeks of conventional wound care. • The wounds must have been present for at least 4 weeks but less than 12 months and have a minimum surface area of 1 cm². • Participants must be in stable general health, as determined by the principal investigator, and not have any contraindications for PRP or EMS therapies, such as active infection, uncontrolled diabetes, or severe cardiovascular disease. • Participants must be capable of providing written informed consent, indicating understanding of the study procedures and potential risks.

Exclusion criteria

Exclusion criteria: • Participants will be excluded if they are under the age of 18, have active infections at the wound site, or have a history of severe allergic reactions to platelet-rich plasma (PRP) therapy or electrical muscular stimulation (EMS). • Individuals with severe cardiovascular, renal, or hepatic conditions, or those with uncontrolled diabetes or autoimmune diseases that may impair wound healing, will also be excluded. • Participants who are pregnant or breastfeeding, or those with a known history of cancer or metastatic disease, will not be eligible. • Individuals who are receiving immunosuppressive therapy or anticoagulants (except low-dose aspirin) or have a history of bleeding disorders will be excluded. • Any patient who has undergone prior wound care treatments that significantly alter healing, such as skin grafting or other advanced regenerative treatments, within the last 6 months will not be included. • Additionally, participants who are unable or unwilling to provide informed consent or comply with study protocols will be excluded.

Design outcomes

Primary

MeasureTime frame
Wound length, width, area, and perimeter will be calculated by tracing the wound using specialized wound measurement software that is imito;

Secondary

MeasureTime frame
Visual Analog Scale ;Wound-QoL questionnaire;

Countries

Pakistan

Contacts

Public ContactSyed Tameem Ul Hassan

Combined Military Hospital Kohat, KPK, Pakistan

drtameem2@gmail.com+92 336 8885877

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026